This chapter points out serious shortcomings in DEA's treatment of price efficiency, illustrates the dangers of misspecification errors in DEA, and suggests extentions of the basic DEA formulation that address these shortcomings.
No takes yet. Share an insight, caveat, or question.
Sexton et al. (1986) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: